Skip to content

Hemodynamic Testing Strategies to Assess Pulmonary Hypertension in Heart Failure

Hemodynamic Testing Strategies to Assess Pulmonary Hypertension and Right Ventricular Function in Heart Failure Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05672719
Enrollment
74
Registered
2023-01-05
Start date
2021-10-19
Completion date
2025-06-30
Last updated
2023-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

The goal of this observational study is to learn about heart function and high lung blood pressure in patients with heart failure. The main question\[s\] it aims to answer are whether we can improve the ability to predict patients who will have complications after they receive treatment including heart transplant and left ventricular assist devices.

Detailed description

Prospective cohort study of patients with heart failure with reduced ejection fraction that are referred for diagnostic right heart catheterization as part of their evaluation for candidacy for advanced heart failure therapies.

Interventions

Procedure

Sponsors

Heart and Stroke Foundation of Canada
CollaboratorOTHER
Mount Sinai Hospital, Canada
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Adults age 18 years or older * Heart failure with reduced ejection fraction (\<40%) * referred for RHC at our centre for evaluation of candidacy for advanced HF therapies.

Exclusion criteria

Severe valvular or complex congenital heart disease Short-term mechanical circulatory support for progressive cardiogenic shock (e.g. extracorporeal membrane oxygenation) Acute coronary syndrome or revascularization occurred within 7 days prior to the RHC. Pregnant or breast-feeding Known hypersensitivity to sodium nitroprusside Advanced liver dysfunction Reduced capacity or inability to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Mean pulmonary artery pressureFirst study 1 day visitHemodynamic measurement
right ventricular end systolic elastanceFirst study 1 day visitHemodynamic measurement
pulmonary arterial elastanceFirst study 1 day visithemodynamic measurement

Secondary

MeasureTime frameDescription
Right ventricular failure after heart transplant1 yearClinical outcome
Right ventricular failure after left ventricular assist device1 yearClinical outcome

Other

MeasureTime frameDescription
right ventricular pulmonary arterial elastance coupling response to vasodilatorFirst study 1 day visitHemodynamic measurement

Countries

Canada

Contacts

Primary ContactSusanna Mak, MD PhD
susanna.mak@sinaihealth.ca4165864800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026